Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 5/2024

22-12-2023 | Urology - Letter to the Editor

Paravesical aggressive angiomyxoma, a rare cause of pelvic tumor in men

Authors: Yaiza María Yáñez-Castillo, María Teresa Melgarejo-Segura, Ana Morales-Martínez, Sara A. Ruiz-Ruiz, Miguel Ángel Arrabal-Polo

Published in: International Urology and Nephrology | Issue 5/2024

Login to get access

Excerpt

Editor, …
Literature
1.
Song M, Glasgow M, Murugan P et al (2017) Aggressive angiomyxoma of the vulva and bladder. Obstet Gynecol 130:885–888CrossRefPubMed
2.
Zugail AS, Baowaidan F, Comperat E-M et al (2018) Angiomyxoma of the ureter imitating an upper tract urothelial carcinoma: a case report. Int J Surg Case Rep 53:39–42CrossRefPubMedPubMedCentral
3.
Zhao C-Y, Su N, Jiang Y-X et al (2018) Application of ultrasound in aggressive angiomyxoma: Eight case reports and review of literature. World J Clin Cases 6:811–819CrossRefPubMedPubMedCentral
4.
Zou R, Xu H, Shi Y et al (2020) Retrospective analysis of clinicopathological features and prognosis for aggressive angiomyxoma of 27 cases in a tertiary center: a 14-year survey and related literature review. Arch Gynecol Obstet 302:219–229CrossRefPubMed
5.
Metadata
Title
Paravesical aggressive angiomyxoma, a rare cause of pelvic tumor in men
Authors
Yaiza María Yáñez-Castillo
María Teresa Melgarejo-Segura
Ana Morales-Martínez
Sara A. Ruiz-Ruiz
Miguel Ángel Arrabal-Polo
Publication date
22-12-2023
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 5/2024
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-023-03921-6

Other articles of this Issue 5/2024

International Urology and Nephrology 5/2024 Go to the issue

Urology - Original Paper

Evaluation of the efficacy and safety of either or both mirabegron and silodosin, as a medical expulsive therapy for distal ureteric stones

Nephrology - Original Paper

Clinical role of serum microRNA-155 in early diagnosis and prognosis of septic patients with acute kidney injury

Nephrology - Original Paper

Evaluation of arteriovenous fistula for hemodialysis with a new generation digital stethoscope: a pilot study

Urology - Original Paper

TRAIP suppressed apoptosis and cell cycle to promote prostate cancer proliferation via TRAF2–PI3K–AKT pathway activation

Urology - Original Paper

Prediction of percutaneous nephrolithotomy outcomes and flexible ureteroscopy outcomes using nephrolithometry scoring systems

Nephrology – Letter to the Editor

Response letter
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits